Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!
May 30, 2017
Roche, Boehringer tout new idiopathic pulmonary fibrosis analyses to boost their rival medications The idiopathic pulmonary fibrosis (IPF) market-share battle between Roche’s Esbriet and Boehringer Ingelheim’s Ofev hasn’t let up since the FDA green-lighted the medications in October 2014. And this week, both drugmak...
Read More...
Dec 02, 2016
Sjögren's syndrome was named on Henrik Sjögren who described this indication in 1933, and is a chronic autoimmune disease in which body’s own immune system and white blood cells attack moisture producing glands such as tear and salivary glands, leading to dry mouth and eyes. There are certain other symptoms involved...
Read More...
Nov 15, 2016
Aurobindo Pharma Q2 net profit up 33.53% to Rs. 606 cr Aurobindo Pharma reported 33.53 per cent rise in consolidated net profit to Rs 605.64 crore for the quarter ending September mainly on account of robust formulation sales. The company had posted a net profit after tax, minority interest and share of profit of jo...
Read More...
Nov 04, 2016
According to National Society of Health, approximately 26 million patients are suffering from heart failure worldwide, with the increased economic burden of USD 30.7 billion each year. The advent of a novel class of drugs, i.e., the angiotensin receptor-neprilysin inhibitor, gives hope to the patients. Neprilysin is...
Read More...
Oct 25, 2016
Boston Biomedical starts phase III study of Napabucasin Boston Biomedical, an industry leader in the development of novel compounds designed to target cancer stemness pathways, announced dosing of the first patient in CanStem303C, a new global phase III study investigating napabucasin in combination with standard of...
Read More...
Jul 07, 2015
DelveInsight expertise over 400+ Indication Active Pharmaceutical Ingredient (API) Reports DelveInsight, leading Market Research and Business Consulting firm has an expertise in providing business solutions to Pharma and biotech companies. DelveInsight has 400+ Indication API reports on wide range of therapeutic ...
Read More...
Aug 19, 2014
The “ Metastatic Prostate Cancer-Pipeline Insights, 2014”, report by DelveInsight provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Metastatic Prostate Cancer. This report provides in...
Read More...
Jul 03, 2014
We DELVEINSIGHT are Business Consultant and Knowledge Partner and have extensive experience across the value chain of pharmaceutical industry. Our company can provide valuable insight across all Pharmaceutical industries which include Drug Manufacturing to API Manufacturers&nb...
Read More...
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Transforming Multiple Myeloma Treatment: The Promise of Novel Drug Classes
Jul 24, 2024
Newsletter/Whitepaper